TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Correlational Study on the Biomarkers Application to the Prediction and Diagnosis of Cardiovascular Diseases

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* stable angina who eligible for coronary angiography after non-invasive stress test.~Exclusion Criteria:~* intolerance to procedure or contarst medium.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- stable angina, biomarker (Type: None): patients with stable angina who received coronary angiography.
- placebo (Type: None): healthy subject

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation and Remission (DEAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Understand and sign the informed consent form.~2. Have documented ulcerative colitis on the basis of usual diagnostic criteria including clinical symptoms and findings from endoscopy, radiology studies, and histology.~3. Have a Simple Clinical Colitis Activity Index (SCCAI)55 score below 3 with no category value greater than 1 (Table 5).~4. Three or fewer bowel movements per 24 hours at the time of enrollment.~5. No visible blood in their bowel movements in the three days prior to enrollment.~6. Have either been on a stable dose of mesalamine medication (oral, rectal or a combination of oral and rectal, including sulfasalazine) or on no mesalamine medications for at least 4 weeks prior to enrollment.~7. Have been on either a stable dose of azathioprine, 6-mercaptopurine, or methotrexate or on none of these medications for at least 8 weeks prior to enrollment.~8. Have experienced at least one flare of ulcerative colitis in the 2 years prior to enrollment. A flare is defined as an increase in stool frequency, bleeding, urgency and/or abdominal discomfort sufficient to warrant a change in medication dose or addition of a new medication.~9. Most recently measured serum creatinine level in the preceding year less than 1.5 mg/dL.~Exclusion Criteria:~1. Age less than 18~2. Inability to speak and read English~3. Presence of an ostomy or prior total or subtotal colectomy~4. Current corticosteroid use or use within the two weeks prior to enrollment~5. Remission for less than 4 weeks prior to enrollment~6. Previous intolerance to mesalamine at doses greater than the current dose.~7. Use of rectally administered mesalamine or steroids within the 2 weeks prior to enrollment.~8. Currently taking more than 3.0 gm/day of mesalamine (oral or rectal). If on oral and rectal mesalamine, the combined dose is more than 3.0 gm/day.~9. Use of anti-TNFα therapies within the 8 weeks prior to enrollment and/or intent to use anti-TNFα therapies as maintenance therapy in the coming 12 weeks.~10. Pregnant or breast feeding women.~11. Use of an experimental therapy for ulcerative colitis in the 8 weeks prior to enrollment.~12. Any condition that the investigator feels will make completion of the study unlikely.~13. Use of cyclosporine in the two weeks prior to enrollment.~14. Moderate or severe abdominal tenderness on examination at time of enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Increase mesalamine dose by 2.4g/day (Type: EXPERIMENTAL): Increase dose of mesalamine by 2.4 gm per day
- Maintain mesalmine dose (Type: NO_INTERVENTION): Maintain current mesalamine dose at 2.4 g/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Automatic Defibrillator Implantation Trial - Reduce Inappropriate Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Primary prevention patient with ischemic or non-ischemic heart disease who meets current guidelines for dual-chamber ICD or CRT-D device therapy~* Patient in sinus rhythm~* Patient on stable optimal pharmacologic therapy for the cardiac condition or who has developed a recent ICD indication that necessitates ICD therapy concurrent with the optimization of pharmacologic therapy~* Patient ≥ 21 years of age, or legal representative, willing and capable of giving informed consent~Exclusion Criteria:~* Patient with an implanted pacemaker or CRT-P~* Patient with existing ICD or CRT-D device components~* Patient with a history of VT or VF~* Patient with permanent or chronic AF, or cardioversion for AF, within the past three calendar months before enrollment~* Patient with coronary artery bypass graft surgery or percutaneous coronary intervention within the past three calendar months prior to enrollment~* Patient with enzyme-positive myocardial infarction within the past three calendar months prior to enrollment~* Patient with angiographic evidence of coronary disease who are candidates for coronary revascularization and are likely to undergo coronary artery bypass graft surgery or percutaneous coronary intervention in the foreseeable future~* Patient with second or third degree heart block~* Patient in NYHA Class IV~* Patient who is pregnant or plans to become pregnant during the course of the trial~* Patient with irreversible brain damage from preexisting cerebral disease~* Patient with presence of any disease, other than the patient's cardiac disease, associated with a reduced likelihood of survival for the duration of the trial, e.g., cancer, uremia, liver failure, etc.~* Patient with chronic renal disease with BUN ≥ 50mg/dl or creatinine ≥ 2.5 mg/dl~* Patient participating in any other clinical trial~* Patient unwilling or unable to cooperate with the protocol~* Patient who lives at such a distance from the clinic that travel for follow-up visits would be unusually difficult~* Patient who does not anticipate being a resident of the area for the scheduled duration of the trial~* Patient unwilling to sign the consent for participation~* Patient whose physician does not allow participation

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Standard ICD Programming
- B (Type: EXPERIMENTAL): High rate cutoff
- C (Type: EXPERIMENTAL): Long ICD duration delay

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be between 50 - 59 years of age~* No fever on day of vaccination~* Females of reproductive potential must be willing to use acceptable form of birth control~Exclusion Criteria:~* Have received chicken pox or shingles vaccine~* Have already had shingles~* Have recently had another vaccination~* Pregnant or breast feeding. Have participated in another research study in the last 30 days~* You are taking certain antiviral drugs~* History of allergic reaction to any vaccine component, including gelatin or neomycin

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- Zostavax™ (Type: EXPERIMENTAL): Participants randomized to receive Zoster Vaccine, Live (Zostavax™).
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomized to receive Placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of MK0524A on Cholesterol Levels (0524A-048)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female between 18 and 70 years of age~* Females of reproductive potential must agree to take acceptable contraceptive precautions for the duration of the study~Exclusion Criteria:~* Patient has a history of not being able to take niacin or niacin-containing products~* Patient consumes more than 2 alcoholic beverages per day~* Patient has poorly controlled Type 1 or Type 2 diabetes mellitus~* Patient engages in vigorous exercise or an aggressive diet regimen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): laropiprant/niacin (MK0524A)
- 2 (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe and Statins on Postprandial Lipemia in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes since at least two years~* Stable metabolic control (HbA1c\<8.0%) for at least six months on diet or diet+oral hypoglycemic drugs (insulin secretagogues or metformin), not to be changed during the study period.~* BMI\<30 kg/m2 and body weight stable during the last six months.~* Both sexes; only post-menopausal women.~* LDL-cholesterol \>130 mg/dl, plasma triglycerides \<400 mg/dl.~* No use of hypolipidemic drugs in the last three months.~Exclusion Criteria:~* Patient with renal (serum creatinine \>1.5 mg/dl) or hepatic (serum transaminases \>three times upper normal values) impairment.~* Patients with history of cardiovascular disease.~* Pre-menopausal women.~* Any other acute or chronic degenerative disease.~* Anemia (Hb\<12 g/dl).~* Uncontrolled blood pressure.~* Use of any drugs able to interfere with the study medications

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): ezetimibe tablets 10 mg/die + simvastatin tablets 20 mg/die six weeks
- 2 (Type: PLACEBO_COMPARATOR): placebo + simvastatin tablets 20 mg/die six weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rehabilitative Trial With tDCS in Amyotrophic Lateral Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of probable, laboratory-supported probable, or definite amyotrophic lateral sclerosis according to the El Escorial revised criteria~* Disease duration ≤ 24 months~* Disease progression in the past 3 months~* Score ≥ 2 at the item swallowing of the ALS Functional Rating Scale Revised~* Score ≥ 2 at the item walking of the ALS Functional Rating Scale Revised~* Treatment with steady regimen of riluzole for a minimum of 1 month before study entry, and desiring its continuation~* Able to give informed consent~* Written informed consent~Exclusion Criteria:~* Motor neuron diseases other than ALS~* Severe head trauma in the past~* History of seizures~* History of ischemic stroke or hemorrhage~* Pacemaker~* Metal implants in the head/neck region~* Severe comorbidity~* Intake of illegal drugs~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Real tDCS (Type: EXPERIMENTAL): 10 days anodal bilateral motor cortex and cathodal spinal tDCS
- Sham tDCS (Type: PLACEBO_COMPARATOR): 10 days sham bilateral motor cortex and sham spinal tDCS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Patient-centered Care Using an Inventory

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Phase I:~* VA patients who have had some experience with care receipt through technology (e.g., home telehealth, CVT, secure messaging with providers).~* A second group will be conducted with patients who have not had experience receiving care through technology.~* There are no other specific inclusion criteria and the investigators plan to recruit both male and female Veterans, as well as minorities.~Phase II:~* Veterans who receive care from VA and are comfortable using the Internet.~* There are no other specific inclusion criteria and the investigators plan to recruit both male and female Veterans, as well as minorities.~Phase III:~* Veterans who receive care from Hines VA or Jesse Brown VA in a primary care/PACT clinic.~* No subjects will be excluded based on gender, race, or ethnicity. Eligibility criteria include:~  * (1) adult, age 18 or over~ * (2) assigned primary care provider in PACT clinic~ * (3) no history of dementia~ * (4) no blindness (unable to view iPad app).~* Only patients of participating providers will be eligible for the study, to ensure both patient and provider consent to audio-recordings and study procedures.~* There are no other specific inclusion criteria and the investigators plan to recruit both male and female Veterans, as well as minorities.~Exclusion Criteria:~* A history of dementia~* Blindness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- patient inventory tool (Type: EXPERIMENTAL): prior to the encounter with his/her provider, the patient completes an inventory that includes information about patient contextual factors (e.g., life circumstances), resources and preferences for care delivery. This information is presented to the provider to facilitate care delivery.
- attention control (Type: ACTIVE_COMPARATOR): prior to the encounter, the patient will view a brief video containing general health information.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Low-dose Intra-articular Tranexamic Acid in Total Knee Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients diagnosed as primary knee osteoarthritis and underwent unilateral primary cemented conventional total knee replacement~* no risk of abnormal bleeding tendency or bleeding disorder (normal coagulogram, serum creatinine \< 2.0 mg/dL, stop nonsteroidal anti-inflammatory drugs and antiplatelet drugs more than 7 days~* no contra-indication for tranexamic acid use (no active intravascular clotting process, no acquired defective colour vision, no subarachnoid hemorrhage, no hypersensitivity to TXA, and no any of history of serious adverse effects, thrombotic disorder and hematuria)~Exclusion Criteria:~* incomplete data collection, for example, malfunctioned drain or accidental drain removal.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): physiologic saline 25 ml
- TXA-250 group (Type: ACTIVE_COMPARATOR): A total of 25-ml solution with 250-mg tranexamic acid
- TXA-500 group (Type: ACTIVE_COMPARATOR): A total of 25-ml solution with 500-mg tranexamic acid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Catheter Ablation Versus Medical Rate Control for Atrial Fibrillation in Patients With Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Age ≥ 18 years, \< 80years~* NYHA II-IV symptoms~* Impairment of left ventricular systolic function (left ventricular ejection fraction estimated as ≤ 35% by radionuclide ventriculography)~* Documented AF lasting for at least 7 days (persistent or permanent AF)~Exclusion criteria:~* CRT or ICD device implanted in the previous 6 months~* AV nodal ablation within previous 3 months~* Prior AV nodal ablation or complete heart block with a single chamber pacemaker~* Contraindication to anticoagulation~* Persistent thrombus in the left atrium despite anticoagulation~* Active malignancy~* Cerebrovascular accident within the previous 6 months~* Reversible causes of AF including thyroid disorders, alcohol, recent surgery~* Reversible causes of heart failure including acute myocarditis or alcohol~* Cardiac events including myocardial infarction (MI), percutaneous coronary intervention (PCI), valve or coronary bypass surgery within the previous 3 months~* Prior AF ablation procedure~* Previous heart transplant, or on urgent heart transplant waiting list~* Severe neuro-muscular disease~* Creatinine clearance \<30 ml/min~* Serum bilirubin \>50 micromol/L~* Active participation in another research study~* Unable to understand and comply with protocol or give written informed consent~* Body mass index \>35 (kg/m2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Rate control (Type: ACTIVE_COMPARATOR): Strategy of 'rate-control': acceptance of atrial fibrillation, and dose-adjusted drug therapy as needed to control ventricular rate.
- Catheter Ablation (Type: ACTIVE_COMPARATOR): Strategy of 'rhythm control' by catheter ablation: patients will undergo catheter ablation with the intention of restoring sinus rhythm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Timely Nudge About Lab Results to Increase myGeisinger Uptake

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Geisinger patient for whom a lab was ordered within 30 days prior to email date~* Patient's lab test result released day before email date~Exclusion Criteria:~* Patient already enrolled in myGeisinger~* Patient has already declined myGeisinger

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Patients do not receive an email
- Timely nudge - view results (Type: EXPERIMENTAL): Patients are emailed about myGeisinger when they have a lab result ready to view. The email includes a View My Lab Results button, which encourages them to click as a pre-commitment step that then brings them to the myGeisinger sign-up page.
- Timely nudge - get started (Type: EXPERIMENTAL): Patients are emailed about myGeisinger when they have a lab result ready to view. The email includes a Get Started With myGeisinger button that is transparent about the next step in the process, before the patient can view test results.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Additive Homeopathy in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Clinical diagnosis of advanced tumor stages of non small-cell lung carcinoma (NSCLC) IIIB, IIIC, IV.~Exclusion Criteria:~* sensitizing mutation of the EGFR gene or translocation of the ALK gene~* refusal to sign informed consent~* pregnancy~* hematological, hepatic, or renal pathology~* coronary heart disease~* history of secondary tumor~* major surgery within 4 weeks prior to study entry~* active infection and symptomatic peripheral neuropathy~* central nervous system metastases unless the metastases were treated and stable~* active autoimmune disease~* use of systemic immunosuppressive treatment~* use of systemic treatment during the previous 2 years~* active interstitial lung disease, or a history of pneumonitis for which glucocorticoids were prescribed~* previous systemic therapy for metastatic disease or previous irradiation~* use of any complementary and/or alternative therapy, including homeopathy other than the research treatment during the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Additive homeopathy in cancer patients (Type: ACTIVE_COMPARATOR): Lung cancer patients receiving conventional chemo- and/or radiation therapy receive additive classical homeopathy with homeopathic globules
- Additive homeopathic placebo globules (Type: PLACEBO_COMPARATOR): Lung cancer patients receiving conventional chemo- and/or radiation therapy receive homeopathic placebo globules
- No intervention (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects at least 18 years of age~* Written informed consent obtained prior to study entry~* Subjects correctly included and having completed clinical studies IC51-301 (NCT00604708) and IC51-302 (NCT00605085) with at least one vaccination~Exclusion Criteria:~* Inability or unwillingness to provide informed consent and to abide the requirements of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete